TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis - PubMed (original) (raw)

doi: 10.1001/jamaneurol.2013.6237.

Erica D Koval 1, Bruno A Benitez 2, Craig Zaidman 1, Jennifer Jockel-Balsarotti 1, Peggy Allred 3, Robert H Baloh 4, John Ravits 5, Ericka Simpson 6, Stanley H Appel 6, Alan Pestronk 1, Alison M Goate 7, Timothy M Miller 8, Carlos Cruchaga 9, Matthew B Harms 8

Affiliations

TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis

Janet Cady et al. JAMA Neurol. 2014 Apr.

Abstract

Importance: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease in which microglia play a significant and active role. Recently, a rare missense variant (p.R47H) in the microglial activating gene TREM2 was found to increase the risk of several neurodegenerative diseases, including Alzheimer disease. Whether the p.R47H variant is a risk factor for ALS is not known.

Objectives: To determine whether p.R47H (rs75932628) in TREM2 is a risk factor for ALS and assess whether TREM2 expression is dysregulated in disease.

Design, setting, and participants: Samples of DNA from 923 individuals with sporadic ALS and 1854 healthy control individuals self-reported as non-Hispanic white were collected from ALS clinics in the United States and genotyped for the p.R47H variant in TREM2. Clinical data were obtained on ALS participants for genotype/phenotype correlations. Expression of TREM2 was measured by quantitative polymerase chain reaction and compared in spinal cord samples from 18 autopsied patients with ALS and 12 neurologically healthy controls, as well as from wild-type and transgenic SOD1G93A mice.

Main outcomes and measures: Minor allele frequency of rs75932628 and relative expression of TREM2.

Results: The TREM2 variant p.R47H was more common in patients with ALS than in the controls and is therefore a significant risk factor for ALS (odds ratio, 2.40; 95% CI, 1.29-4.15; P = 4.1×10-3). Furthermore, TREM2 expression was increased in spinal cord samples from ALS patients and SOD1G93A mice (P = 2.8×10-4 and P = 2.8×10-9, respectively), confirming dysregulated TREM2 in disease. Expression of TREM2 in the human spinal cord was negatively correlated with survival (P = .04) but not with other phenotypic aspects of disease.

Conclusions and relevance: This study demonstrates that the TREM2 p.R47H variant is a potent risk factor for sporadic ALS. To our knowledge, these findings identify the first genetic influence on neuroinflammation in ALS and highlight the TREM2 signaling pathway as a therapeutic target in ALS and other neurodegenerative diseases.

PubMed Disclaimer

Figures

Figure 1

Figure 1. TREM2 expression is increased in human ALS and SOD1G93R mouse spinal cord

TREM2 expression was measured by qPCR in A) lumbar spinal cord sections from 18 ALS subjects and 12 controls and normalized to the geometric mean of three endogenous control genes. B) In mice, expression was measured in spinal cords from 8 SODG93R mice and 6 wild-type littermates with normalization to an endogenous control. p-values were calculated using two-tailed student’s t-test.

Similar articles

Cited by

References

    1. Engelhardt JI, Appel SH. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch Neurol. 1990 Nov;47(11):1210–1216. - PubMed
    1. Chiu IM, Morimoto ET, Goodarzi H, et al. A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 2013 Jul 25;4(2):385–401. - PMC - PubMed
    1. Liao B, Zhao W, Beers DR, Henkel JS, Appel SH. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol. 2012 Sep;237(1):147–152. - PMC - PubMed
    1. Kierdorf K, Prinz M. Factors regulating microglia activation. Front Cell Neurosci. 2013;7:44. - PMC - PubMed
    1. Takahashi K, Rochford CD, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med. 2005 Feb 21;201(4):647–657. - PMC - PubMed

Publication types

MeSH terms

Substances

Supplementary concepts

Grants and funding

LinkOut - more resources